Australia Urged to Lead Global Effort Against Childhood Dementia
CANBERRA, Australia, Sept. 9 2024 /PRNewswire/ -- A groundbreaking new report, "State of Childhood Dementia in Australia 2024," released today at Australia's Parliament House in Canberra by the Childhood Dementia Initiative, has revealed the devastating impact of childhood dementia on Australian families. Childhood Dementia Initiative calls for urgent action to address systemic barriers to cures, treatments, and adequate healthcare and...
A. Menarini Diagnostics and Nucleix announce a strategic partnership for a non-invasive bladder cancer test in Europe
Under the commercial agreement, A. Menarini Diagnostics will assume exclusive marketing of the non-invasive Bladder EpiCheck® test in Europe in the months ahead, providing patients and clinicians with a urine test to detect and monitor recurrence of bladder cancer and upper tract urothelial carcinoma (UTUC). FLORENCE, Italy, Sept. 9, 2024 /PRNewswire/...
Three Study Results Abstracts From Kelun-Biotech’s TROP2-ADC SKB264 (sac-TMT) At 2024 ESMO Released Today
CHENGDU, China, Sept. 9, 2024 /PRNewswire/ -- The European Society for Medical Oncology (ESMO) Congress 2024 will be held in Barcelona, Spain from September 13 to 17, 2024. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd（"Kelun-Biotech", 6990.HK）will present the following results of its anti-TROP2 ADC sacituzumab tirumotecan (sac-TMT, formerly SKB264/MK-2870). 1.Efficacy and safety of sac-TMT plus pembrolizumab (KEYTRUDA®) in...
EQT to acquire GeBBS Healthcare Solutions, a leading healthcare technology solutions provider
GeBBS Healthcare Solutions ("GeBBS" or the "Company") specializes in revenue cycle management, health information management (HIM), and medical billing services It offers a range of services designed to help US-based healthcare providers, including hospitals, health systems, and physician practices, improve their financial performance by optimizing revenue cycle processes and ensuring accurate coding and billing practices Drawing on its...
Senhwa Biosciences Presents Clinical Data Abstract on Pidnarulex at 2024 ESMO Congress
The study involved end-stage oncology patients with no other suitable treatment options. In this Phase Ib study, Pidnarulex (CX-5461) demonstrated acceptable clinical tolerability and showed preliminary signs of efficacy, even in patients who had previously failed treatment with PARP inhibitors. Out of 15 patients who were evaluable for drug response,...
Antennova to Present Latest Data of ATN-037 in a Mini Oral Presentation at ESMO Congress 2024
BOSTON, Sept. 9, 2024 /PRNewswire/ -- Antennova, a clinical-stage biotech company focused on oncology today announced that it will present the latest data of CD73 small molecule inhibitor ATN-037 in a Mini Oral presentation at the 2024 European Society of Medical Oncology Congress (ESMO Congress 2024), taking place from September 13th to September...
ESMO 2024 | Ascentage Pharma to Present Updated Data of Olverembatinib in Patients with SDH-Deficient GIST during a Mini Oral Presentation at the 2024 ESMO Congress
ROCKVILLE, Md. and SUZHOU, China, Sept. 9, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class therapies for malignancies, today announced that it will present the latest clinical data of olverembatinib (HQP1351), the company's novel drug candidate, in patients with succinate dehydrogenase-...
Major Release of Veeva Site Connect Streamlines Clinical Trial Execution for Sites and Sponsors
New capabilities and simple, standard site experience cut trial time and expenseFixed price implementation to get up and running quicklyIndustry advances to connected trials as seven of the top 20 biopharmas adopt Veeva Site Connect SYDNEY, Sept. 9, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced, in a major step forward for clinical...
Perioperative Ivonescimab (PD-1/VEGF) for NSCLC Demonstrated Clinically Significant Phase II Results, Presented in Oral Session at WCLC 2024
HONG KONG, Sept. 9, 2024 /PRNewswire/ -- Akeso (9926. HK) announced that its internally developed PD-1/VEGF bispecific antibody ivonescimab showed clinically significant results from a Phase II study, either as a monotherapy or in combination with chemotherapy, for the perioperative treatment of resectable non-small cell lung cancer (NSCLC) at the 25th World Conference on Lung Cancer (WCLC). This...
Bc Babycare Marks a Stellar Debut at Germany’s Kind+Jugend 2024
COLOGNE, Germany, Sept. 6, 2024 /PRNewswire/ -- Bc Babycare, a leader in innovative products for mothers and babies, made a remarkable debut at Kind+Jugend 2024, the premier international trade fair for baby and toddler outfitting, which opened in Cologne, Germany, on September 3. The brand captivated industry-wide attention with its exceptional designs and groundbreaking technology. Bc Babycare Debuts at...
